Hormone replacement therapy after breast cancer: Attitudes of women eligible in a randomized trial

Climacteric

Volumn 12, Issue 6, 2009, Pages 478-489

  Wallberg, B ^a   Von Schoultz, E ^b   Bolund, C ^a   Bergh, J ^a   Wilking, N ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast cancer; Hormone replacement therapy; Randomized study

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER PATIENT; CANCER RISK; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PATIENT ATTITUDE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT OUTCOME; TUMOR VOLUME; UNCERTAINTY; UNSPECIFIED SIDE EFFECT;

AGED; ATTITUDE TO HEALTH; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT PREFERENCE; POSTMENOPAUSE; QUESTIONNAIRES; RESEARCH; RISK FACTORS; SWEDEN;

EID: 70449632823     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130902912597     Document Type: Article

References (32)

1. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210
2. Falkeborn M, Person I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progesteron replacement. Br J Obstet Gynaecol 1992;99: 821-828
3. Falkeborn M, Persson I, Terént A, Adami HO, Lithell H, Bergström R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153:1201-1209
4. Kiel DP, Felson DT, Andersson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;17: 1169-1174
5. Stamper M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
6. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-297 (Pubitemid 19193804)
7. Steinberg KA, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-1990
8. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
9. Chlebowski RT, Hendrix SL, Langer RD, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289:3243-3253
10. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
11. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57 (Pubitemid 34705518)
12. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362: 419-427
13. Holmberg L, Andersson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?) a randomised comparison: trial stopped. Lancet 2004;363:453-455 (Pubitemid 38210063)
14. von Schoultz E, Rutqvist LE on behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial. J Natl Cancer Inst 2005;97:533-535
15. DewJE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002;5:151-155
16. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks NPM. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible? Fertil Steril 2000;73: 292-299
17. Kenemans P, Bundred NJ, Foidart J-M, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-146
18. Holmberg L, Iversen O-E, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-482
19. Rippy L, Marsden M. Is HRT justified for symptom management in women at higher risk of developing breast cancer? Climacteric 2006;9: 404-415
20. Thurstone LL. A law of comparative judgement. In Maranell GM, ed. Scaling: A Sourcebook for Behavioural Scientists. Chicago, IL: Aldine, 1974:81-92
21. Wallberg B, Michelson H, Nystedt M, Bolund C, Degner LF, Wilking N. Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients. Acta Oncol 2000;39:467-476
22. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277: 1485-1492
23. Beaver K, Luker KA, Owens RG, Leinster SJ, Degner LF. Treatment decision making in women newly diagnosed with breast cancer. Cancer Nurs 1995;18:1-12
24. Slevin M, Mossman J, Bowling A, et al. Volunteers or victims: Patients' views of randomised clinical trials. Br J Cancer 1995;71: 1270-1274
25. Sloan JA, Doig W, Yeang A. A manual to carry out Thurstone scaling and related analytic procedures. Manitoba Nursing Research Institute Technical Report 11. University of Manitoba, Canada, 1994
26. Vassilopoulou-Sellin R, Klein MJ. Estrogen replacement therapy after treatment for localized breast carcinoma, patient responses and opinions. Cancer 1996;78:1043-1048
27. Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001;84:48-51
28. Cassileth BR, Lusk EJ, Miller DS, Hurwitz S. Attitudes toward clinical trials among patients and the public. JAMA 1982;248:968-970
29. Jenkins V, Fallowfield LJ. Reasons for accepting or declining to participate in randomised clinical trials of cancer therapy. Br J Cancer 2000;82: 1783-1788
30. Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol 2000;11: 939-945
31. Jensen AB, Madsen B, Andersen P, Rose C. Information for cancer patients entering a clinical trial - an evaluation of an information strategy. Eur J Cancer 1993;16A:2235-2238
32. Ganz PA, Greendale GA, Kahn B O'Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer 1999;86:814-820